Arginine attenuates methylglyoxal- and high glucose-induced endothelial dysfunction and oxidative stress by an endothelial nitric-oxide synthase-independent mechanism

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 1, 2012, Pages 196-204

  Dhar, Indu ^a   Dhar, Arti ^a   Wu, Lingyun ^a   Desai, Kaushik M ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCYSTEINE; ARGINASE; ARGININE; DEXTRO ARGININE; DICARBOXYLIC AMINO ACID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N EPSILON CARBOXYETHYLLYSINE; N(G) NITROARGININE METHYL ESTER; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; AORTA; ARGINASE; ARGININE; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PYRUVALDEHYDE; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; VASCULAR DISEASES; VASODILATION;

EID: 84862497436     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.192112     Document Type: Article

References (52)

1. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, and Baynes JW (1997) N-ε-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 324:565-570.
2. Beisswenger P and Ruggiero-Lopez D (2003) Metformin inhibition of glycation processes. Diabetes Metab 29:6S95-103.
3. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, Kim S, Burke S, Shoukas AA, Nyhan D, Champion HC, et al. (2003) Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108:2000-2006. (Pubitemid 37296546)
4. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, et al. (2004) Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24:32-40. (Pubitemid 38250484)
5. Brownlee M, Vlassara H, Kooney A, Ulrich P, and Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232:1629-1632. (Pubitemid 16095602)
6. Desai KM, Sessa WC, and Vane JR (1991) Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature 351:477-479. (Pubitemid 21896622)
7. Desai KM and Wu L (2008) Free radical generation by methylglyoxal in tissues. Drug Metabol Drug Interact 23:151-173. (Pubitemid 351669569)
8. Dhar A, Desai K, Kazachmov M, Yu P, and Wu L (2008) Methylglyoxal production in vascular smooth muscle cells from different metabolic precursors. Metab Clin Exp 57:1211-1220.
9. Dhar A, Desai K, Liu J, and Wu L (2009) Methylglyoxal, protein binding and biological samples: are we getting the true measure? J Chromatogr B Analyt Technol Biomed Life Sci 877:1093-1100.
10. Dhar A, Desai KM, and Wu L (2010a) Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats. Br J Pharmacol 159:166-175.
11. Dhar A, Dhar I, Desai KM, and Wu L (2010b) Methylglyoxal scavengers attenuate endothelial dysfunction induced by methylglyoxal and high concentrations of glucose. Br J Pharmacol 161:1843-1856.
12. Dhar A, Dhar I, Jiang B, Desai KM, and Wu L (2011) Chronic methylglyoxal infusion by minipump causes pancreatic β-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 60:899-908.
13. Edelstein D and Brownlee M (1992) Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41:26-29.
14. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, and Spinowitz BS (1999) Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20:493-510. (Pubitemid 29460926)
15. 5-(5-hydroxy-4, 6-dimethylpyrimidine-2-yl)-l-ornithine, a novel methylglyoxal-arginine modification in beer. J Agric Food Chem 49:366-372.
16. Goumas G, Tentolouris C, Tousoulis D, Stefanadis C, and Toutouzas P (2001) Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis 154:255-267. (Pubitemid 32146597)
17. Haraguchi Y, Takiguchi M, Amaya Y, Kawamoto S, Matsuda I, and Mori M (1987) Molecular cloning and nucleotide sequence of cDNA for human liver arginase. Proc Natl Acad Sci U S A 84:412-415. (Pubitemid 17006205)
18. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
19. Ishizaka M, Nagai A, Iwanaga M, Imamura M, and Azuma H (2007) Possible involvement of enhanced arginase activity due to up-regulated arginases and decreased hydroxyarginine in accelerating intimal hyperplasia with hyperglycemia. Vascul Pharmacol 47:272-280. (Pubitemid 350008128)
20. Jia X, Olson DJ, Ross AR, and Wu L (2006) Structural and functional changes in human insulin induced by methylglyoxal. FASEB J 20:1555-1557.
21. Jia X and Wu L (2007) Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Mol Cell Biochem 306:133-139. (Pubitemid 350001825)
22. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, and Hanssen KF (2003) Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metab Clin Exp 52:163-167. (Pubitemid 36388837)
23. Lo TW, Westwood ME, McLellan AC, Selwood T, and Thornalley PJ (1994) Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N-α-acetylarginine, N-α-acetylcysteine, and N-α-acetyllysine, and bovine serum albumin. J Biol Chem 269:32299-32305.
24. McLellan AC, Thornalley PJ, Benn J, and Sonksen PH (1994) Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 87:21-29. (Pubitemid 24220267)
25. Millea PJ (2009) N-acetylcysteine: multiple clinical applications. Am Fam Physician 80:265-269.
26. Moncada S, Palmer RM, and Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142.
27. Morris SM Jr (2009) Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 157:922-930.
28. Morris SM Jr, Bhamidipati D, and Kepka-Lenhart D (1997) Human type II arginase: sequence analysis and tissue-specific expression. Gene 193:157-161. (Pubitemid 27294602)
29. Mostafa AA, Randell EW, Vasdev SC, Gill VD, Han Y, Gadag V, Raouf AA, and El Said H (2007) Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol Cell Biochem 302:35-42. (Pubitemid 47202318)
30. Palmer RM, Ashton DS, and Moncada S (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666.
31. Pollock JS, Förstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, and Murad F (1991) Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A 88:10480-10484. (Pubitemid 21915859)
32. Potenza MA, Gagliardi S, Nacci C, Carratu' MR, and Montagnani M (2009) Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 16:94-112.
33. Rabbani N, Godfrey L, Xue M, Shaheen F, Geoffrion M, Milne R, and Thornalley PJ (2011) Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes 60:1973-1980.
34. Rees DD, Palmer RM, Hodson HF, and Moncada S (1989) A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 96:418-424. (Pubitemid 19045118)
35. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, and Caldwell RW (2008) Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102:95-102.
36. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, and Wiernsperger N (1999) Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 58:1765-1773. (Pubitemid 29505417)
37. Schulz R, Smith JA, Lewis MJ, and Moncada S (1991) Nitric oxide synthase in cultured endocardial cells of the pig. Br J Pharmacol 104:21-24.
38. Shipanova IN, Glomb MA, and Nagaraj RH (1997) Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Arch Biochem Biophys 344:29-36. (Pubitemid 27328093)
39. Su Y, Liu XM, Sun YM, Jin HB, Fu R, Wang YY, Wu Y, and Luan Y (2008) The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int J Clin Pract 62:877-882. (Pubitemid 351691505)
40. Takahashi K (1977) The reactions of phenylglyoxal and related reagents with amino acids. J Biochem 81:395-402.
41. Thornalley PJ (1988) Modification of the glyoxalase system in human red blood cells by glucose in vitro. Biochem J 254:751-755.
42. Thornalley PJ (1993) The glyoxalase system in health and disease. Mol Aspects Med 14:287-371.
43. Thornalley PJ (1996) Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 27:565-573.
44. Thornalley PJ, Hooper NI, Jennings PE, Florkowski CM, Jones AF, Lunec J, and Barnett AH (1989) The human red blood cell glyoxalase system in diabetes mellitus. Diabetes Res Clin Pract 7:115-120. (Pubitemid 19221706)
45. Vander Jagt DL and Hunsaker LA (2003) Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chem Biol Interact 143-144:341-351. (Pubitemid 36253593)
46. Vasdev S, Ford CA, Longerich L, Parai S, Gadag V, and Wadhawan S (1998) Aldehyde induced hypertension in rats: prevention by N-acetyl cysteine. Artery 23:10-36. (Pubitemid 30045665)
47. Wang H, Meng QH, Gordon JR, Khandwala H, and Wu L (2007) Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus. Clin Biochem 40:1232-1239. (Pubitemid 47562425)
48. Wang X, Jia X, Chang T, Desai K, and Wu L (2008) Attenuation of hypertension development by scavenging methylglyoxal in fructose-treated rats. J Hypertens 26:765-772. (Pubitemid 351354925)
49. Wei LH, Jacobs AT, Morris SM Jr, and Ignarro LJ (2000) IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol 279:C248-C256. (Pubitemid 30616638)
50. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, et al. (1998) Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 95:4630-4634.
51. Wu L and Juurlink BH (2002) Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 39:809-814. (Pubitemid 34252881)
52. Zhang C, Hein TW, Wang W, Chang CI, and Kuo L (2001) Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 15:1264-1266.